NRX Pharmaceuticals Q2 EPS $(0.12) Beats $(0.14) Estimate
Portfolio Pulse from mahesh@benzinga.com
NRX Pharmaceuticals reported Q2 losses of $(0.12) per share, beating the analyst consensus estimate of $(0.14) by 14.29%. However, this represents a 9.09% increase in losses compared to the same period last year.
August 14, 2023 | 8:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
NRX Pharmaceuticals reported better than expected Q2 losses, but the losses increased compared to last year.
While NRX Pharmaceuticals beat the analyst consensus estimate for Q2, the increase in losses compared to the same period last year could potentially offset any positive sentiment. This makes the short term impact on the stock price neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100